Market Research Report
Global Autoimmune Disorder Drug Delivery Devices Market: Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030
|Published by||BIS Research Inc.||Product code||968659|
|Published||Content info||247 Pages
Delivery time: 1-2 business days
|Global Autoimmune Disorder Drug Delivery Devices Market: Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030|
|Published: October 29, 2020||Content info: 247 Pages||
"Global Autoimmune Disorders Drug Delivery Devices Market to Reach $10,686.5 Million by 2030."
AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Biogen Inc., Merck KGaA, Bayer AG, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Eli Lily and Company, Sanofi S.A., UCB Inc., and Takeda Pharmaceutical Company Limited, among others
Healthcare experts have found the autoimmune disorders industry to be one of the most rapidly evolving markets. The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. The market is driven by certain factors, including the increasing global geriatric population, increasing incidence of chronic diseases including autoimmune disorders, and rise in demand for self-injectable systems.
The market is favored by the development of autoimmune disorder drug delivery devices for several clinical areas such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. The increase in the geriatric population and incurable autoimmune disorders across the globe are expected to translate into a significantly higher demand for autoimmune disorder drug delivery devices.
Furthermore, the companies are investing huge amounts in research and development of autoimmune disorder drug delivery devices. The clinical trial landscape of different autoimmune disorders has been on the rise in recent years, and this will drive the autoimmune disorder drug delivery devices market in the future.
Within the research report, the market is segmented based on indication, product type, manufacturing type, and region. Each of these segments covers the market's snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buzz among companies to invest in the development of novel autoimmune disorder drug delivery devices. Due to the leading market products and intense market penetration, Amgen Inc. has been a pioneer in this field and has been a significant competitor in this market.
Several other companies, such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, have launched drug delivery devices for autoimmune disorders.
Based on region, North America holds the largest share of the autoimmune disorder drug delivery devices market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at a high CAGR during the forecast period.